Welcome to our dedicated page for Inhibikase Therapeutics news (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics stock.
Inhibikase Therapeutics Inc (IKT) is a clinical-stage pharmaceutical company pioneering protein kinase inhibitors for neurodegenerative disorders, including Parkinson's disease. This page serves as the definitive source for official announcements, clinical trial updates, and strategic developments from the company.
Investors and researchers will find curated updates on drug pipeline progress, regulatory milestones, and scientific advancements. Our collection includes earnings reports, partnership announcements, preclinical study results, and FDA correspondence related to candidates like Risvodetinib (IkT-148009) and IkT-001Pro.
All content is rigorously verified to ensure compliance with financial disclosure standards. Bookmark this page for real-time updates on:
• Clinical trial phases for Parkinson's-focused therapies
• Regulatory filings and agency interactions
• Peer-reviewed research publications
• Strategic collaborations in neurodegenerative research
For stakeholders tracking kinase inhibitor development and neurodegenerative treatment innovation, this resource provides essential updates directly from Inhibikase Therapeutics' corporate communications.
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) announced the closure of its public offering of 15 million shares at $3.00 each, raising gross proceeds of $45 million. This funding aims to support a Phase 1b extension study for IkT-148009 targeting Parkinson's disease, production for upcoming clinical trials, and general R&D activities. The underwriters also have a 45-day option to purchase an additional 2.25 million shares. The offering was registered with the SEC and the final prospectus is available online.
Inhibikase Therapeutics (Nasdaq: IKT) announced a public offering of 15 million shares at $3.00 each, totaling approximately $45 million in gross proceeds. The offering will close on June 18, 2021, subject to customary conditions. Proceeds will fund a Phase 1b extension study for IkT-148009 in Parkinson's patients, production for subsequent studies, and general R&D efforts. The underwriters have a 45-day option to purchase an additional 2.25 million shares. The offering is registered with the SEC under Form S-1.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced that CEO Dr. Milton Werner will present at two upcoming virtual healthcare conferences. The first is the Jefferies Virtual Healthcare Conference on June 1, 2021, at 3:30 PM ET, followed by the LD Micro Virtual Invitational XI on June 10, 2021, at 11:30 AM ET. Dr. Werner will discuss the clinical pharmacokinetics and adverse event profile of IkT-148009, the company's leading treatment for Parkinson's disease. Webcasts will be available for on-demand viewing on the company's website for 30 days after each event.
Inhibikase Therapeutics (Nasdaq: IKT) reported Q1 2021 financial results, highlighting key developments in its Parkinson's disease treatment programs. The company accelerated the Phase 1 study of IkT-148009, aiming for regulatory approval to begin patient dosing by Q3 2021. Toxicology studies for IkT-148009 are ongoing, with an IND application for IkT-001Pro planned for submission in Q3 2021. Financially, Inhibikase reported a net loss of $2.6 million, up from $0.5 million in Q1 2020, with R&D expenses rising to $2.4 million due to clinical trial costs. Cash reserves stood at $9.6 million.
Inhibikase Therapeutics (NASDAQ: IKT) announced that CEO Milton Werner, Ph.D., will present at the Sachs 4th Annual Neuroscience Innovation Forum from April 28-30, 2021. He will discuss clinical measures related to IKT-148009, a treatment for Parkinson's disease, focusing on dosing pharmacokinetics and its mechanism of action. Dr. Werner will also partake in a panel discussion on Parkinson's and Movement Disorders on April 28 at 1:20 p.m. ET. The company is developing therapeutics for Parkinson's and related disorders, currently conducting Phase I studies on IKT-148009.
Inhibikase Therapeutics (IKT) reported financial results for Q4 and the full year 2020, noting a net loss of $1.21 million in Q4, improving from $0.43 million in Q4 2019. For the full year, the net loss was $2.85 million, down from $5.72 million in 2019. The company completed its IPO in December 2020, raising approximately $14.60 million. In early 2021, it commenced patient dosing for IkT-148009, aimed at treating Parkinson's disease, and initiated chronic toxicology studies. Cash reserves stood at $13.95 million as of year-end 2020, supporting ongoing research initiatives.
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) announced that CEO Milton Werner, Ph.D., will present at the H.C. Wainwright & Co. Global Life Sciences Virtual Conference on March 9, 2021. This online presentation can be accessed in the Investors section of their website starting at 7:00 am ET. The webcast will be available for approximately 90 days post-event. Inhibikase focuses on developing therapeutics for Parkinson's disease, with its lead program IkT-148009 currently in Phase I trials assessing its safety and pharmacokinetics.
Inhibikase Therapeutics (Nasdaq: IKT) announced it will present findings on its oral therapy IkT-148009 for Parkinson's disease at the virtual ASENT 2021 Annual Meeting from February 22-25, 2021. CEO Milton Werner, Ph.D., will showcase the therapeutic effects observed in humanized mouse models, emphasizing the role of alpha-synuclein plaques in disease progression. The presentation is scheduled for February 25, 2021, at 10:20 AM ET, followed by a panel discussion. IkT-148009, currently in Phase 1 trials, aims to modify Parkinson's disease progression.
Inhibikase Therapeutics (Nasdaq: IKT) has initiated dosing in a Phase 1 clinical trial for IkT-148009, a c-Abl inhibitor targeting Parkinson’s disease. This study focuses on the safety and pharmacokinetics of IkT-148009 in healthy volunteers aged 45-70. The drug has shown promise in preclinical studies for halting and reversing functional loss in Parkinson's. CEO Milton Werner expressed that this milestone could lead to a transformative therapy for millions. Parkinson’s affects approximately 1 million people in the U.S., highlighting the significance of Inhibikase’s research.
Inhibikase Therapeutics (Nasdaq: IKT) has partnered with Clintrex Research Corporation to enhance its clinical development for Parkinson's disease and related disorders. Clintrex will manage clinical trials and regulatory aspects for Inhibikase's drug candidates, including IkT-148009 and IkT-001Pro. Dr. C. Warren Olanow, CEO of Clintrex, will take on the role of Interim Chief Medical Officer for Inhibikase. This collaboration aims to expedite the clinical advancement of treatments targeting serious neurological conditions.
FAQ
What is the current stock price of Inhibikase Therapeutics (IKT)?
What is the market cap of Inhibikase Therapeutics (IKT)?
